BackFSD Pharma Overview

FSD Pharma Current Cash

Track FSD Pharma's current cash ($3.3M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$3.31M
↓ 41.69% YoYΔ $-2.36M vs prior year quarter

Peer trimmed avg / median

Loading

FSD Pharma Current Cash History

Loading

FSD Pharma vs. peers: Current Cash Comparison

Loading

FSD Pharma Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

FSD Pharma (HUGE) FAQ

FSD Pharma (HUGE) currently reports a current cash of $3.3M as of June 2024. That compares with $5.7M in the prior-year period — down 41.7% year over year. Use the charts on this page to explore FSD Pharma's current cash history and peer comparisons.

FSD Pharma's current cash decreased from $5.7M to $3.3M — a 41.7% year-over-year decrease (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

FSD Pharma reported $3.3M in current cash as of June 2024. That compares with $5.7M in the prior-year period — down 41.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $3.3M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for FSD Pharma, and consider following HUGE for alerts when major investors trade the stock.

FSD Pharma is classified in the Healthcare sector. On current cash, it currently shows $3.3M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HUGE with unrelated industries.